Northwest Biotherapeutics Inc

OTCQB:NWBOUnited States

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and included treatment of a diverse range of more than a dozen types of cancers. The Company’s wholly owned subsidiaries include Flaskworks, LLC, Northwest Biotherapeutics Limited, Aracaris Capital, Ltd, Northwest Biotherapeutics B.V., and NW Bio GmbH.

Contact Information

Headquarters

SUITE 800, 4800 MONTGOMERY LANEBETHESDA, MD, United States 20814

Phone

240-497-9024

Fax

302-636-5454

Executives

Chairperson of the Board, President, Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer

Linda Powers

Senior Vice President, General Counsel

Leslie Goldman

Chief Scientific Officer, Corporate Secretary, Director

Alton Boynton

Chief Technical Officer

Marnix Bosch

Independent Director

J. Cofer Black